收藏切换
Promoting China's model of innovative drug pricing rules
收藏切换
Shanlian HU
World Clinical Drug | 2024, 45(3) : 233 - 238
Less
收藏切换
World Clinical Drug | 2024, 45(3): 233-238
• Recommendation •
Promoting China's model of innovative drug pricing rules
Full
Shanlian HU
Affiliations
  • Department of Health Economics, School of Public Health, Fudan University, Shanghai 200032, China
Published: 2024-03-10 doi: 10.13683/j.wph.2024.03.001
Outline
收藏切换
Objective

To introduce the contents, significance of the policy on ''Notice on Establishing Initial Launching Market Price Formation for Newly Original Chemicals and Encouraging High-Quality Innovation'' issued by the China Healthcare Security Administration in 2024 and put forward suggestions for improvement.

Methods

The contents and requirements of economic analysis of new drugs with high, middle and low innovative degrees were summarized through policies analysis and literature review, the classification of added benefits of innovative drugs in America, Germany, France and Canada was compared.

Results

Great progress has been made in the research and development of innovative drugs in China in recent years. We should adhere to the basic principle that drug prices should be determined by the market, and give full play to the role of the government in supporting and guiding the prices of newly listed drugs. The innovation degree of new drugs is evaluated from three dimensions: pharmaceutical basis, clinical value and evidence-based information. The evaluation system consists of 3 first-grade indexes, 13 second-grade indexes and 34 third-grade indexes, which are classified into high (90 — 150 scores), middle (50 — 90 scores) and low (below 50 scores) categories according to the scores value, to guide pharmaceutical companies to self-evaluating the innovation degree of newly listed chemicals.

Conclusion

The new policy encourages the development of high-quality innovative drugs, and takes the clinical value as the priority, paying attention on the added therapeutic benefit assessment. The new policy clarifies the composition of the ''basket'' and ''initial price'' of countries and regions of external reference pricing that has been established in China. The composition including 5 parts, the manufacturing costs, production period costs, sales profits, taxes, and distributor/wholesaler's mark-up. It should fully mobilize the initiative of free-pricing system by the pharmaceutical enterprises, recommendation from trade associations, clinical professional opinions issued by medical institutions, mobilize the enthusiasm of health technology assessment agencies and multi-disciplinary experts, finally conduct the social co-governance of drug prices in China.

chemical  /  launching market price  /  high-quality development  /  market mechanism  /  independent pricing
胡善联. 开启中国模式的创新药物定价规则. 世界临床药物, 2024 , 45 (3) : 233 -238 . DOI: 10.13683/j.wph.2024.03.001
Shanlian HU. Promoting China's model of innovative drug pricing rules[J]. World Clinical Drug, 2024 , 45 (3) : 233 -238 . DOI: 10.13683/j.wph.2024.03.001
Year 2024 volume 45 Issue 3
10
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.03.001
  • Receive Date:2023-03-01
  • Online Date:2026-11-18
  • Published:2024-03-10
Article Data
Affiliations
History
  • Received:2023-03-01
Affiliations
    Department of Health Economics, School of Public Health, Fudan University, Shanghai 200032, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.03.001
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT